

# KASHYAP TELE-MEDICINES LIMITED

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02

Corp. Off. : "Suryarath", 1<sup>st</sup> Floor, Panchwati, 1<sup>st</sup> Lane, Ambawadi, Ahmedabad – 06

Phone: (079) (71001500), Email: [investor.relations@jindalonline.com](mailto:investor.relations@jindalonline.com)

CIN: L29110MH1995PLC085738

---

Date: 19<sup>th</sup> May, 2018

To,  
Bombay Stock Exchange Ltd.  
Listing Department  
Phiroz Jeejeebhoy Tower,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai-400001

Scrip Code – 531960

Dear Sir/Madam,

**Sub:** Submission of the Audited Financial Results for the quarter and year ended on 31<sup>st</sup> March, 2018 pursuant to Regulation 33 of the SEBI (LODR), Regulations, 2015

Pursuant to Regulation 33 of the SEBI (LODR), Regulations, 2015 please find enclosed Audited Financial Results of the Company along with a copy of Auditors' Report for the quarter and year ended 31<sup>st</sup> March, 2018 approved by the Board of Directors at their meeting held today i.e. on Saturday, 19<sup>th</sup> May, 2018.

Kindly take this on your record and oblige.

Thanking you.

Yours faithfully,  
For Kashyap Tele-Medicines Limited



Dhruvil Shah  
Company Secretary &  
Compliance Officer



Encl: As above



# SAREMAL & CO

## Chartered Accountants

CA Saremal shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

### Independent Auditors Report

#### For the quarter and year ended Statement of Financial Results of Kashyap Tele-Medicines Limited Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors of  
Kashyap Tele-Medicines Limited

1. We have audited the accompanying statement of Financial Results of Kashyap Tele-Medicines Limited (the 'Company'), for the quarter and year ended on March 31, 2018 (the 'statement') attached herewith being submitted by Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015 read with SEBI circulars CIR/CFD/CMD/15/2015 dated November 30, 2015 and CIR/CFD/FAC/62/2016 dated July 5, 2016. Attention is drawn to the fact that the figures for the quarter ended March 31, 2018 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between the audited figures in respect of full financial year and the published year to date figures up to the end of the third quarter of the financial year, which were subject to limited review by us.
2. These financial results are based on the annual IND AS financial statements for the year ended March 31, 2018 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting standards ('IND AS 25/ IND AS 34') specified under section 133 of the Companies Act, 2013 ('the act'), which is the responsibility of the company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our audit of such IND AS financial Statements which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ('IND AS'), prescribed under section 133 of the Companies Act 2013 read with relevant rules issued there under; as applicable and other accounting principles generally accepted in India.
3. We conducted our audit in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and the significant estimates made by the Management. We believe that our audit provides a reasonable basis for our opinion.



4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:

(i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circulars CIR/CFD/CMD/15/2015 dated November 30, 2015 and CIR/CFD/FAC/62/2016 dated July 5, 2016.

(ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information of the Company for the quarter and year ended March 31, 2018.

5. The review of audited Standalone Financial Results for the corresponding quarter and year ended 31<sup>st</sup> March, 2017 prepared in accordance with applicable Accounting Standards (previous GAAP) was carried out by the predecessor auditor vide their unmodified reports dated 29<sup>th</sup> May, 2017 respectively, whose reports have been furnished to us by the management and which have been relied upon by us for the purpose of our review of the financial statement. Our review report is not modified in respect of this matter.

Date: 19/05/2018  
Place: Ahmedabad



For SAREMAL & CO.  
Chartered Accountants

A handwritten signature in black ink, appearing to be "Pravin Lavana".

Pravin Lavana  
(Partner)

Membership No.: 037180  
Firm Registration No.: 109281W

**KASHYAP TELE-MEDICINES LIMITED**  
 Regd. Off: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Mumbai- 400 002  
 CIN: L29110MH1995PLC085738 , Email Id: investor.relations@jindalonline.com  
 Audited Financial Results for the quarter and year ended 31-03-2018

( ₹ in Lacs except EPS)

S.No.	Particulars	Quarter Ended			Year Ended	
		31/3/2018	31/12/2017	31/3/2017	31/3/2018	31/3/2017
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from operations	4.65	4.65	4.05	18.00	15.45
II	Other Income	0.07	0.00	0.00	0.11	0.09
III	<b>Total Revenue ( I + II )</b>	<b>4.72</b>	<b>4.65</b>	<b>4.05</b>	<b>18.11</b>	<b>15.54</b>
IV	<b>Expenses</b>					
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	1.62	1.91	1.29	6.27	5.11
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	1.83	1.80	1.54	6.91	5.80
	<b>Total expenses</b>	<b>3.45</b>	<b>3.71</b>	<b>2.83</b>	<b>13.18</b>	<b>10.91</b>
V	<b>Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>1.27</b>	<b>0.94</b>	<b>1.22</b>	<b>4.93</b>	<b>4.63</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit before extraordinary items and tax (V - VI )</b>	<b>1.27</b>	<b>0.94</b>	<b>1.22</b>	<b>4.93</b>	<b>4.63</b>
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX	<b>Profit before tax ( VII- VIII)</b>	<b>1.27</b>	<b>0.94</b>	<b>1.22</b>	<b>4.93</b>	<b>4.63</b>
X	Tax expense :-					
	(a) Current tax	0.00	0.24	0.83	0.94	0.88
	(b) Deferred tax	0.00	0.00	0.00	0.00	0.00
XI	<b>Profit / (Loss) for the period from continuing operations (IX - X)</b>	<b>1.27</b>	<b>0.70</b>	<b>0.39</b>	<b>3.99</b>	<b>3.75</b>
XII	<b>Profit/(loss) from discontinuing operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Tax expense of discontinuing operations</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIV	<b>Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XV	<b>Profit / (Loss) for the period (XI + XIV )</b>	<b>1.27</b>	<b>0.70</b>	<b>0.39</b>	<b>3.99</b>	<b>3.75</b>
XVI	<b>Share of profit / (loss) of associates*</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XVII	<b>Minority interest</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XVIII	<b>Profit / (Loss) after Taxes</b>	<b>1.27</b>	<b>0.70</b>	<b>0.39</b>	<b>3.99</b>	<b>3.75</b>
	<b>Other Comprehensive Income</b>					
XIX	<b>A. Items that will be/will not be reclassified through profit and loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
	<b>B. Income Tax Relating to Items that will be/will not be reclassified through profit and loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XX	<b>Paid-up equity share capital (Face Value of Rs. 1/- each)</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>
	<b>Earnings per equity share:</b>					
XXI	(a) Basic (XVIII/XX)	0.003	0.001	0.001	0.008	0.008
	(b) Diluted (XVIII/XX)	0.003	0.001	0.001	0.008	0.008

Place : Ahmedabad  
 Date : 19th May, 2018



*(Handwritten signature)*




For, Kashyap Tele - Medicines Limited

*(Handwritten signature)*  
 Amit Agrawal  
 Managing Director  
 DIN:00169061

**KASHYAP TELE-MEDICINES LIMITED**  
 Regd. Off: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Mumbai- 400 002  
 CIN L29110MH1995PLC085738, Email Id: investor.relations@jindalonline.com  
**BALANCE SHEET AS AT 31<sup>ST</sup> MARCH, 2018**

Particulars	As at 31.03.2018	As at 31.03.2017
<b>ASSETS</b>		
<b>I Non-Current Assets</b>		
(a) Property, Plant and Equipment	-	-
(b) Capital work in progress	-	-
(c) Financial Assets	-	-
(i) Investments	21	21
(ii) Other Financial Assets	0.34	0.34
(d) Other Non-Current Assets	191.69	191.69
	<b>213.03</b>	<b>213.03</b>
<b>II Current Assets</b>		
(a) Inventories	-	-
(b) Financial assets	-	-
(i) Trade Receivables	12.25	12.25
(ii) Cash and Cash Equivalents	11.42	6.43
(iii) Investments	-	-
(iv) Loans	0.12	0.34
(c) Other Current Assets	0.25	0.25
(d) Accrued Interest - FDR	-	-
	<b>24.05</b>	<b>19.27</b>
<b>TOTAL ASSETS</b>	<b>237.08</b>	<b>232.30</b>
<b>EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
(a) Share Capital	489.20	489.20
(b) Other Equity	(254.51)	(258.50)
	<b>234.69</b>	<b>230.70</b>
<b>II Non Current Liabilities</b>		
(a) Long term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
	<b>-</b>	<b>-</b>
<b>III Current Liabilities</b>		
(a) Financial liabilities		
(i) Short term borrowings	-	-
(ii) Trade Payables	0.88	0.29
(iii) Other Financial liabilities	-	-
(b) Other Current Liabilities	0.57	0.43
(c) Short-Term Provisions	-	-
(d) Income tax liabilities	0.94	0.88
	<b>2.39</b>	<b>1.60</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>237.08</b>	<b>232.30</b>

Place : Ahmedabad  
 Date : 19th May, 2018




For, Kashyap Tele-Medicines Limited

  
 Amit Agrawal  
 Managing Director  
 DIN:00169061



# KASHYAP TELE-MEDICINES LIMITED

(Formerly Known as JINDAL ONLINE.COM LTD.)

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –02

E-mail: [investor.relations@jindalonline.com](mailto:investor.relations@jindalonline.com) CIN: L29110MH1995PLC085738

## Notes:

1. The above Unaudited Financial Results of the company for the quarter and year ended on March 31, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 19/05/2018.
2. The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulation, 2015 ( as amended).
3. The Statutory Auditors of the Company have carried out Limited Review of the above Audited Financial Results for the quarter and year ended on March 31, 2018 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
4. The company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
5. Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.
6. The reconciliation of Net Profit or loss to the total comprehensive income as reported under previous General Accepted Accounting Principles (GAAP) and as per Ind AS for the quarter and year ended 31<sup>st</sup> March, 2018 is given below:

Particulars	Quarter ended	Year ended on
	31/03/2017	31/03/2017
Total comprehensive income for the period as per previous GAAP	0.39	3.75
Add/Less:		
Nil Adjustments	0.00	0.00
<b>Total comprehensive income for the period as per Ind AS</b>	<b>0.39</b>	<b>3.75</b>

7. The figures for the corresponding previous periods have been restated/regrouped wherever necessary, to make them comparable.

Date: 19<sup>th</sup> May, 2018

Place: Ahmedabad



For Kashyap Tele-Medicines Limited



Amit Agrawal  
Managing Agrawal  
DIN: 00169061